Literature DB >> 28573509

Temporal Changes in the Modes of Hepatitis C Virus Transmission in the USA and Northern China.

Elizabeth Wu1, Ming Yang2, Huiying Rao2, Sherry Fu1, Bo Feng2, Ran Fei2, Andy Lin3, Robert J Fontana1, Lai Wei2, Anna S Lok4.   

Abstract

BACKGROUND: Predominant modes of hepatitis C virus (HCV) transmission vary between countries and over time. AIMS: To compare HCV transmission modes in the USA and northern China.
METHODS: We conducted a prospective study enrolling two cohorts of chronic HCV patients in the USA, and in China at Beijing, and at Gu'an and Kuancheng counties in Hebei. Patients self-reported the most likely source and year of infection.
RESULTS: A total of 1957 patients were studied (1000 USA; 957 China-428 Beijing, 387 Gu'an, 142 Kuancheng). The predominant infection sources were transfusion (23.0%) and injection drug use (IDU) (32.1%) in the USA and transfusion (64.5%) in northern China. Within China, transfusion was the most common source in Beijing (62.1%) and Gu'an (88.1%), and medical procedures (35.9%) and IDU (12.0%) in Kuancheng. Infection via transfusion decreased significantly in the USA (35.1-4.6%) and Beijing (84.2-14.3%) but remained frequent in Gu'an (90.5-72.5%) over time. Infection via IDU decreased from 32.4% in those ≥61 years to 25.0% in those 41-50 years but increased to 46.5% in those ≤40 years in US patients and decreased over time from 38.7 to 1.9% in Kuancheng. Infection via medical procedures increased over time in Beijing (7.0-33.3%) and remained frequent in Kuancheng (45.2-31.1%).
CONCLUSIONS: There are major differences in presumed HCV infection source between the USA and northern China. Favorable as well as worrisome changes in the modes of HCV transmission in both countries were observed.

Entities:  

Keywords:  Blood transfusion; Epidemiology; Hepatitis C virus; Injection drug use; Medical procedures

Mesh:

Year:  2017        PMID: 28573509     DOI: 10.1007/s10620-017-4619-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

Review 1.  Blood banking in China.

Authors:  Hua Shan; Jing-Xing Wang; Fu-Rong Ren; Yuan-Zhi Zhang; Hai-Yan Zhao; Guo-Jing Gao; Yang Ji; Paul M Ness
Journal:  Lancet       Date:  2002-11-30       Impact factor: 79.321

Review 2.  Hepatitis C virus infection in the United States.

Authors:  M J Alter
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

3.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors:  Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

4.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

5.  Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006.

Authors:  Ian T Williams; Beth P Bell; Wendi Kuhnert; Miriam J Alter
Journal:  Arch Intern Med       Date:  2011-02-14

6.  The global burden of disease attributable to contaminated injections given in health care settings.

Authors:  Anja M Hauri; Gregory L Armstrong; Yvan J F Hutin
Journal:  Int J STD AIDS       Date:  2004-01       Impact factor: 1.359

7.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

8.  Prevalence and characterization of hepatitis B and C virus infections in a needle-sharing population in Northern China.

Authors:  Cheng-Jun Xu; Cui-Ping Zhang; Bi-Fen Luo; Li-Jun Liu; Yun-Zhong Wang; Xiao-Hong Wang; Qiu-Jie He; Shan-Shan Zhou; Wei-Shan Guo; Jiu-Heng Wang; Rui-Feng Yang; Hai-Ying Zhang; Hui-Ying Rao; Bo Feng; Lai Wei
Journal:  BMC Public Health       Date:  2015-05-02       Impact factor: 3.295

9.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

10.  Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection.

Authors:  Huiying Rao; Lai Wei; Juan Carlos Lopez-Talavera; Jia Shang; Hong Chen; Jun Li; Qing Xie; Zhiliang Gao; Lei Wang; Jia Wei; Jianning Jiang; Yongtao Sun; Ruifeng Yang; Hong Li; Haiying Zhang; Zuojiong Gong; Lunli Zhang; Longfeng Zhao; Xiaoguang Dou; Junqi Niu; Hong You; Zhi Chen; Qin Ning; Guozhong Gong; Shuhuan Wu; Wei Ji; Qing Mao; Hong Tang; Shuchen Li; Shaofeng Wei; Jian Sun; Jiaji Jiang; Lungen Lu; Jidong Jia; Hui Zhuang
Journal:  J Gastroenterol Hepatol       Date:  2014-03       Impact factor: 4.029

View more
  2 in total

Review 1.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

Review 2.  The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine.

Authors:  Joseph Torresi
Journal:  Front Microbiol       Date:  2017-11-07       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.